|Expense ratio (net)||N/A|
|Last cap gain||N/A|
|Morningstar risk rating||N/A|
|Beta (5Y monthly)||N/A|
|5y average return||N/A|
|Average for category||N/A|
LAVAL, Quebec , Feb. 19, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to amend and refinance its existing credit agreement (the "Credit Agreement") in order to extend and reprice its existing term loan facility and revolving credit facility and make certain other amendments to the terms of the facilities in connection therewith (collectively, the "Credit Agreement Refinancing"). Additionally, the Company intends, subject to market conditions, to have Bausch Health Americas, Inc. ("BHA"), a wholly-owned indirect subsidiary of the Company, issue $3.25 billion of secured debt securities (the "New Debt Securities").
LAVAL, Quebec , Feb. 3, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the application process for its 2020 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a $10,000 scholarship in support of their academic goals.
LAVAL, Quebec , Oct. 10, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the 2019 Aspire Higher scholarship program recipients. The program, which since 2013 has granted more than $648,000 in scholarships to students who have been affected by dermatologic conditions, will award nine students with scholarships of $10,000 each to pursue their undergraduate or graduate degrees.